Truist Securities Maintains Buy on Edgewise Therapeutics, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Edgewise Therapeutics and increased the price target from $25 to $33, indicating confidence in the company's future performance.
September 19, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has increased its price target for Edgewise Therapeutics from $25 to $33 while maintaining a Buy rating, suggesting a positive outlook for the company's stock.
The increase in price target from $25 to $33 by Truist Securities, along with the maintained Buy rating, indicates strong confidence in Edgewise Therapeutics' future performance. This is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100